The purpose of this book is to provide a contemporary overview of the causes and consequences of prostate cancer from a cellular and genetic perspective. Written by experts in the fields of epidemiology, toxicology, cell biology, genetics, genomics, cell-cell interactions, cell signaling, hormone signaling, and transcriptional regulation, the text covers aspects of prostate cancer from disease initiation to metastasis. Chapters explore in depth the cells of origin for prostate cancer, its genomic subtypes, neural transcription factors in disease progression, epigenetic regulation of chromatin, and many other topics. This book distinguishes itself from other texts on prostate cancer by its focus on cellular and genetic mechanisms, as opposed to clinical diagnosis and management. As a result, this book will be of broad interest to basic and translational scientists with familiarity of these topics, as well as to trainees at earlier stages of their research careers.

This guide covers every aspect of prostate cancer, from potential causes including diet to tests for diagnosis, curative treatment, and innovative means of controlling advanced stages of cancer.

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

Reveals how fear-based and inaccurate testing is resulting in unnecessary high-risk surgeries, arguing that the PSA test was never intended for prostate cancer screening.

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.

Looks at the effectiveness of the prostatectomy and surveys the latest research in prostate cancer managment.

Prostate cancer is the most common form of cancer (excluding skin cancer) among American men. In 1998 approximately 184,500 new cases of prostate cancer were diagnosed in the United States. However, if detected early, it is also among the most treatable forms of cancer, and due to advances in diagnosis and treatment, survival rates continue to rise. The five-year survival rate has increased from 50 percent in the period from 1960 to 1963 to 89 percent today. But most men--and their families--lack the most basic information about what to do when confronted with a diagnosis of prostate cancer. This book, written by internationally respected medical experts, sets out to explain everything a man needs to know. Written, updated, and revised under the auspices of the American Cancer Society, the nation's leader in cancer research, education, and rehabilitation, it contains the most up-to-date information about the disease. Even more, it is a patient's advocacy book, offering medical, practical, psychological, social, and emotional support. Through case histories and anecdotes--and always with compassion--it addresses the full range of issues that men with the disease may face.